As life sciences sector's positive momentum continues, so do executive compensation levels

Article metrics

  • 125 Accesses

Non-founder total target cash compensation in 2017 increased 8.3% year-over-year at private life sciences companies and 6.4% at private technology companies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2
Figure 3: Screenshot of a sample CompStudy target severance histogram from the 2017 survey.

References

  1. 1

    Rychlik, B. Nat. Biotechnol. 35, 383–386 (2017).

  2. 2

    Rychlik, B. Nat. Biotechnol. 34, 667–670 (2016).

  3. 3

    Wasserman, N. The Founder's Dilemmas: Anticipating and Avoiding the Pitfalls That Can Sink a Startup (Princeton University Press, 2012).

Download references

Author information

Correspondence to Bruce Rychlik.

Ethics declarations

Competing interests

The author declares competing interests. Cognition Therapeutics is a former client of Park Square Executive Research.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rychlik, B. As life sciences sector's positive momentum continues, so do executive compensation levels. Nat Biotechnol 36, 661–664 (2018) doi:10.1038/nbt.4188

Download citation